Literature DB >> 9291439

Vascular endothelial growth factor (VEGF) in human breast cancer: correlation with disease-free survival.

A Obermair1, E Kucera, K Mayerhofer, P Speiser, M Seifert, K Czerwenka, A Kaider, S Leodolter, C Kainz, R Zeillinger.   

Abstract

Studies have shown that microvessel density influences breast-cancer prognosis. Since tumor angiogenesis is considered to be substantially affected by the excretion of vascular endothelial growth factor (VEGF) from tumor cells, we examined whether VEGF concentration is different in malignant and in non-malignant breast tissue. It was also of interest to discover whether intratumoral VEGF concentration influences disease-free survival (DFS) of breast-cancer patients. Analysis is based on 120 tissue specimens taken from breast fibromas (n = 23), normal epithelial breast tissue adjacent to fibromas (n = 8) and invasive breast cancer (n = 89). VEGF concentration was quantified by using an immunoassay. Microvessel density was determined by immunostaining for factor-VIII-related antigen. Median VEGF concentration is given in pg/mg protein (25%-quantile-75%-quantile) and it was 0 (0-1.8) in normal breast tissue, 9.8 (0.52-43.0) in fibromas and 130.4 (50.8-362.2) in invasive carcinomas. A univariate Cox model revealed that node status, tumor size, estrogen-receptor concentration, histological grading and microvessel density were prognostic factors for disease-free survival in breast cancer. We found a significant correlation between VEGF concentration and microvessel count, but VEGF concentration did not significantly influence disease-free survival. Although VEGF protein was found at a significantly higher concentration in malignant than in non-malignant tissue, determination of intratumoral VEGF protein by an enzyme immunoassay was not prognostically relevant in our patient population.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9291439     DOI: 10.1002/(sici)1097-0215(19970822)74:4<455::aid-ijc17>3.0.co;2-8

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  25 in total

Review 1.  Angiogenesis and melanoma.

Authors:  J P Dutcher
Journal:  Curr Oncol Rep       Date:  2001-07       Impact factor: 5.075

2.  The vascular-ablative agent VEGF(121)/rGel inhibits pulmonary metastases of MDA-MB-231 breast tumors.

Authors:  Sophia Ran; Khalid A Mohamedali; Troy A Luster; Philip E Thorpe; Michael G Rosenblum
Journal:  Neoplasia       Date:  2005-05       Impact factor: 5.715

3.  Regulation of vascular endothelial growth factor (VEGF) gene transcription by estrogen receptors alpha and beta.

Authors:  M D Mueller; J L Vigne; A Minchenko; D I Lebovic; D C Leitman; R N Taylor
Journal:  Proc Natl Acad Sci U S A       Date:  2000-09-26       Impact factor: 11.205

4.  Vascular endothelial growth factor (VEGF) in astrocytic gliomas--a prognostic factor?

Authors:  R D Oehring; M Miletic; M M Valter; T Pietsch; J Neumann; R Fimmers; U Schlegel
Journal:  J Neurooncol       Date:  1999       Impact factor: 4.130

5.  Prospective study of eukaryotic initiation factor 4E protein elevation and breast cancer outcome.

Authors:  Benjamin D L Li; Jeffrey S Gruner; Fleurette Abreo; Lester W Johnson; Herbert Yu; Soheir Nawas; John C McDonald; Arrigo DeBenedetti
Journal:  Ann Surg       Date:  2002-05       Impact factor: 12.969

6.  The vascular-targeting fusion toxin VEGF121/rGel inhibits the growth of orthotopic human bladder carcinoma tumors.

Authors:  Khalid A Mohamedali; Daniel Kedar; Paul Sweeney; Ashish Kamat; Darren W Davis; Beryl Y Eve; Samuel Huang; Philip E Thorpe; Colin P Dinney; Michael G Rosenblum
Journal:  Neoplasia       Date:  2005-10       Impact factor: 5.715

7.  Quantitation of Vascular Endothelial Growth Factor and Interleukin-6 in Different Stages of Breast Cancer.

Authors:  Kabbathi Raghunathachar Sahana; Prashant Akila; Vishwanath Prashant; Bellekere Sharath Chandra; Maduvanahalli Nataraj Suma
Journal:  Rep Biochem Mol Biol       Date:  2017-10

8.  Expression of vascular endothelial growth factor, hypoxia inducible factor 1alpha, and carbonic anhydrase IX in human tumours.

Authors:  A M Jubb; T Q Pham; A M Hanby; G D Frantz; F V Peale; T D Wu; H W Koeppen; K J Hillan
Journal:  J Clin Pathol       Date:  2004-05       Impact factor: 3.411

9.  Overexpression of vascular endothelial growth factor 189 in breast cancer cells leads to delayed tumor uptake with dilated intratumoral vessels.

Authors:  Marie-Astrid Hervé; Hélène Buteau-Lozano; Roger Vassy; Ivan Bieche; Guillaume Velasco; Marika Pla; Gérard Perret; Samia Mourah; Martine Perrot-Applanat
Journal:  Am J Pathol       Date:  2007-12-13       Impact factor: 4.307

Review 10.  Genetically engineered mice as experimental tools to dissect the critical events in breast cancer.

Authors:  Mitchell E Menezes; Swadesh K Das; Luni Emdad; Jolene J Windle; Xiang-Yang Wang; Devanand Sarkar; Paul B Fisher
Journal:  Adv Cancer Res       Date:  2014       Impact factor: 6.242

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.